Pentadecapeptide BPC 157 as Therapy for Inferior Caval Vein Embolization: Recovery of Sodium Laurate-Post-Embolization Syndrome in Rats
-
Published:2023-10-23
Issue:10
Volume:16
Page:1507
-
ISSN:1424-8247
-
Container-title:Pharmaceuticals
-
language:en
-
Short-container-title:Pharmaceuticals
Author:
Smoday Ivan Maria1, Krezic Ivan1, Kalogjera Luka1ORCID, Vukovic Vlasta1ORCID, Zizek Helena12, Skoro Marija2, Kovac Katarina Kasnik12, Vranes Hrvoje1ORCID, Barisic Ivan1, Sikiric Suncana3, Strbe Sanja1, Tepes Marijan1, Oroz Katarina1, Zubcic Slavica1, Stupnisek Mirjana1ORCID, Beketic Oreskovic Lidija1, Kavelj Ivana2, Novosel Luka2, Prenc Matea2, Barsic Ostojic Sanja2, Dobric Ivan4, Sever Marko4, Blagaic Alenka Boban1, Skrtic Anita3ORCID, Staresinic Mario4, Sjekavica Ivica2, Seiwerth Sven3, Sikiric Predrag1ORCID
Affiliation:
1. Department of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia 2. Department of Diagnostic and Interventional Radiology, University Hospital Centre, 10000 Zagreb, Croatia 3. Department of Pathology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia 4. Department of Surgery, School of Medicine, University of Zagreb,10000 Zagreb, Croatia
Abstract
After inferior caval vein embolization therapy, post-embolization syndrome (sodium laurate 10 mg/kg, 0.1 mL into rat inferior caval vein, assessment at 15, 30, 60 min, prime lung lesions, thromboemboli occluding lung vessels), as a severe occlusion/occlusion-like syndrome, might be resolved as a whole by stable gastric pentadecapeptide BPC 157 therapy. At 5 min after laurate injection, stable gastric pentadecapeptide BPC 157 was implemented as therapy (10 µg/kg, 10 ng/kg intraperitoneally or intragastrically). As before, confronted with the occlusion of major vessel(s) or similar noxious procedures, such as rapidly acting Virchow triad circumstances, the particular effect of the therapy (i.e., collateral pathways activation, “bypassing vascular key”, i.e., direct blood flow delivery via activation of azygos vein) assisted in the recovery of the vessel/s and counteracted multiorgan failure due to occlusion/occlusion-like syndrome as a whole in the laurate-injected rats. Along with prime lung lesions and thromboemboli occluding lung vessels, post-embolization syndrome rapidly occurred peripherally and centrally as a shared multiorgan and vessel failure, brain, heart, lung, liver, kidney, and gastrointestinal tract lesions, venous hypertension (intracranial (superior sagittal sinus), portal, and caval), aortal hypotension, progressing thrombosis in veins and arteries and stasis, congested and/or failed major veins, and severe ECG disturbances. Whatever the cause, these were all counteracted, eliminated, or attenuated by the application of BPC 157 therapy. As recovery with BPC 157 therapy commonly and rapidly occurred, reversing the collapsed azygos vein to the rescuing collateral pathway might initiate rapid direct blood delivery and start blood flow reorganization. In conclusion, we suggest BPC 157 therapy to resolve further vascular and embolization injuries.
Funder
University of Zagreb
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference75 articles.
1. Pentadecapeptide BPC 157 and the central nervous system;Vukojevic;Neural Regen. Res.,2022 2. Stable gastric pentadecapeptide BPC 157 and wound healing;Seiwerth;Front. Pharmacol.,2021 3. Stable gastric pentadecapeptide BPC 157, Robert’s stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye’s stress coping response: Progress, achievements, and the future;Sikiric;Gut Liver,2020 4. BPC 157 rescued NSAID-cytotoxicity via stabilizing intestinal permeability and enhancing cytoprotection;Park;Curr. Pharm. Des.,2020 5. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing;Sikiric;Curr. Pharm. Des.,2018
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|